Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30455% above fair value
$286.94−11.77 (-3.94%)
Close on Nov 19, 2026Market cap $5.74BP/E 125.3Yield –
Ligand Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Ligand Pharmaceuticals's pe ratio was 33.7× on Nov 11, 2026, against 105.3× a year earlier. Over the last 5 years it ranged from 2.3× to 105.3×, with a median of 38.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 33.7× | −64.3 |
| 2025 | Dec 31, 2025 | 98.0× | +55.3 |
| 2024 | Dec 31, 2024 | 42.7× | −48.9 |
| 2023 | Dec 29, 2023 | 91.6× | +23.9 |
| 2022 | Jul 29, 2022 | 67.7× | +29.0 |
| 2021 | Dec 31, 2021 | 38.7× | +35.6 |
| 2020 | Apr 30, 2020 | 3.1× | −0.7 |
| 2019 | Dec 31, 2019 | 3.8× | −20.5 |
| 2018 | Dec 31, 2018 | 24.2× | +6.6 |
| 2017 | Dec 29, 2017 | 17.6× | −281.2 |
| 2016 | Dec 30, 2016 | 298.9× | +288.8 |
| 2015 | Dec 31, 2015 | 10.1× | −156.2 |
| 2014 | Dec 31, 2014 | 166.3× | +63.1 |
| 2013 | Dec 31, 2013 | 103.1× | −193.1 |
| 2012 | Dec 31, 2012 | 296.3× | +272.1 |
| 2011 | Dec 30, 2011 | 24.2× | – |
See a number that looks wrong?